JP2021510695A5 - - Google Patents
Info
- Publication number
- JP2021510695A5 JP2021510695A5 JP2020538573A JP2020538573A JP2021510695A5 JP 2021510695 A5 JP2021510695 A5 JP 2021510695A5 JP 2020538573 A JP2020538573 A JP 2020538573A JP 2020538573 A JP2020538573 A JP 2020538573A JP 2021510695 A5 JP2021510695 A5 JP 2021510695A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound
- pharmaceutically acceptable
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127398A JP7817214B2 (ja) | 2018-01-12 | 2023-08-03 | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
| JP2025061337A JP2025106370A (ja) | 2018-01-12 | 2025-04-02 | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616768P | 2018-01-12 | 2018-01-12 | |
| US201862617134P | 2018-01-12 | 2018-01-12 | |
| US62/617,134 | 2018-01-12 | ||
| US62/616,768 | 2018-01-12 | ||
| US201862728514P | 2018-09-07 | 2018-09-07 | |
| US62/728,514 | 2018-09-07 | ||
| PCT/US2019/013315 WO2019140272A1 (en) | 2018-01-12 | 2019-01-11 | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127398A Division JP7817214B2 (ja) | 2018-01-12 | 2023-08-03 | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510695A JP2021510695A (ja) | 2021-04-30 |
| JP2021510695A5 true JP2021510695A5 (https=) | 2022-01-18 |
| JP7538040B2 JP7538040B2 (ja) | 2024-08-21 |
Family
ID=65324563
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538573A Active JP7538040B2 (ja) | 2018-01-12 | 2019-01-11 | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
| JP2023127398A Active JP7817214B2 (ja) | 2018-01-12 | 2023-08-03 | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
| JP2025061337A Pending JP2025106370A (ja) | 2018-01-12 | 2025-04-02 | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127398A Active JP7817214B2 (ja) | 2018-01-12 | 2023-08-03 | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
| JP2025061337A Pending JP2025106370A (ja) | 2018-01-12 | 2025-04-02 | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11718642B2 (https=) |
| EP (2) | EP4706761A3 (https=) |
| JP (3) | JP7538040B2 (https=) |
| MA (1) | MA51568A (https=) |
| TW (1) | TW201930269A (https=) |
| WO (1) | WO2019140272A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| TW201930269A (zh) | 2018-01-12 | 2019-08-01 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| KR20220112803A (ko) * | 2019-12-05 | 2022-08-11 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| CN111233815B (zh) * | 2020-01-21 | 2022-10-14 | 上海应用技术大学 | 一种异阿根廷蚁素的制备方法 |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL48628A0 (en) * | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| NZ298567A (en) * | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| ATE284895T1 (de) | 1995-06-06 | 2005-01-15 | Euro Celtique Sa | Neuroaktive steroide der androstan- und pregnanreihe |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| BR112020012761A2 (pt) | 2017-12-22 | 2021-02-17 | Sage Therapeutics, Inc. | composições e métodos para o tratamento de distúrbios do snc |
| TW201930269A (zh) | 2018-01-12 | 2019-08-01 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| WO2019154257A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| CN109503694A (zh) | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| KR20250174100A (ko) | 2018-12-05 | 2025-12-11 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| CN113272315B (zh) | 2018-12-26 | 2023-08-08 | 张家口华健致远生物科技有限公司 | 一类类固醇化合物及其用途 |
| WO2021188778A2 (en) | 2020-03-18 | 2021-09-23 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
-
2019
- 2019-01-11 TW TW108101261A patent/TW201930269A/zh unknown
- 2019-01-11 MA MA051568A patent/MA51568A/fr unknown
- 2019-01-11 US US16/961,097 patent/US11718642B2/en active Active
- 2019-01-11 WO PCT/US2019/013315 patent/WO2019140272A1/en not_active Ceased
- 2019-01-11 EP EP25209494.1A patent/EP4706761A3/en active Pending
- 2019-01-11 EP EP19703816.9A patent/EP3737687B1/en active Active
- 2019-01-11 JP JP2020538573A patent/JP7538040B2/ja active Active
-
2023
- 2023-06-05 US US18/328,865 patent/US12421275B2/en active Active
- 2023-08-03 JP JP2023127398A patent/JP7817214B2/ja active Active
-
2025
- 2025-04-02 JP JP2025061337A patent/JP2025106370A/ja active Pending
- 2025-08-06 US US19/291,992 patent/US20260078143A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021510695A5 (https=) | ||
| JP2023119042A5 (https=) | ||
| JP2022510683A5 (https=) | ||
| JP2022534424A5 (https=) | ||
| JP2022504607A5 (https=) | ||
| JP2023537632A5 (https=) | ||
| JP2017531020A5 (https=) | ||
| JP2022538300A5 (https=) | ||
| CA2271566C (en) | Substituted phenyl pyrimidines useful in the treatment of cns disorders | |
| JP2023531517A5 (https=) | ||
| JP2022514385A5 (https=) | ||
| JP2018505898A5 (https=) | ||
| JP2019520417A5 (https=) | ||
| JP2022538301A5 (https=) | ||
| RU2009133259A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| RU2014122335A (ru) | ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGluR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ | |
| NZ724602A (en) | Ror-gamma modulators and uses thereof | |
| JP2009526831A5 (https=) | ||
| JP2023518411A5 (https=) | ||
| ES2711425T3 (es) | Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos | |
| JP2021512098A5 (https=) | ||
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| JP2024520654A5 (https=) | ||
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| JP2015522606A5 (https=) |